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ORIGINAL ARTICLE
Reactive Oxygen Species Mediate Human
Hepatocyte Injury During
Hypoxia/Reoxygenation
Ricky Harminder Bhogal, Stuart M. Curbishley, Christopher J. Weston, David H. Adams,
and Simon C. Afford
Centre for Liver Research, Institute for Biomedical Research, Medical School, University of Birmingham,
Birmingham, United Kingdom
Increasing evidence shows that reactive oxygen species (ROS) may be critical mediators of liver damage during the relative hy-
poxia of ischemia/reperfusion injury (IRI) associated with transplant surgery or of the tissue microenvironment created as a
result of chronic hepatic inﬂammation or infection. Much work has been focused on Kupffer cells or liver resident macrophages
with respect to the generation of ROS during IRI. However, little is known about the contribution of endogenous hepatocyte
ROS production or its potential impact on the parenchymal cell death associated with IRI and chronic hepatic inﬂammation. For
the ﬁrst time, we show that human hepatocytes isolated from nondiseased liver tissue and human hepatocytes isolated from
diseased liver tissue exhibit marked differences in ROS production in response to hypoxia/reoxygenation (H-R). Furthermore,
several different antioxidants are able to abrogate hepatocyte ROS–induced cell death during hypoxia and H-R. These data
provide clear evidence that endogenous ROS production by mitochondria and nicotinamide adenine dinucleotide phosphate
oxidase drives human hepatocyte apoptosis and necrosis during hypoxia and H-R and may therefore play an important role in
any hepatic diseases characterized by a relatively hypoxic liver microenvironment. In conclusion, these data strongly suggest
that hepatocytes and hepatocyte-derived ROS are active participants driving hepatic inﬂammation. These novel ﬁndings high-
light important functional/metabolic differences between hepatocytes isolated from normal donor livers, hepatocytes isolated
from normal resected tissue obtained during surgery for malignant neoplasms, and hepatocytes isolated from livers with end-
stage disease. Furthermore, the targeting of hepatocyte ROS generation with antioxidants may offer therapeutic potential for
the adjunctive treatment of IRI and chronic inﬂammatory liver diseases. Liver Transpl 16:1303-1313, 2010. VC 2010
AASLD.
Received June 2, 2010; accepted July 23, 2010.
Most studies that have investigated the mechanisms of
liver damage occurring as a result of ischemia/reperfusion
injury (IRI) have focused on the setting of liver transplanta-
tion. It is equally possible that relatively hypoxic conditions
can occur during other episodes of hepatic inﬂammation
or established chronic disease. Hepatocytes exposed to a
hypoxic microenvironment would therefore be potentially
sensitized to cell death, although no studies have yet
explored this process in primary human hepatocytes.
Despite considerable advances in surgical practice
and more judicious use of immunosuppression, he-
patic IRI continues to adversely affect allograft func-
tion and survival after orthotopic liver transplantation
(OLT). Toledo-Pereyra et al.1 in 1975 were among the
ﬁrst to note the detrimental effects of IRI during ex-
perimental liver transplantation. IRI is a proinﬂamma-
tory, antigen-independent process that culminates in
hepatocyte injury. The potential processes regulating
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hepatic IRI have been summarized in recent
reviews.2,3 Recent studies have suggested that hepatic
IRI accounts for up to 10% of early allograft failures
and is associated with a higher incidence of both
acute and chronic rejection.4 The primary cellular tar-
get during IRI is the hepatocyte. Hepatocyte death
seen during the hypoxic and reperfusion phases of IRI
occurs within a relatively hypoxic environment, and
hepatic IRI can be divided into 2 phases. The early
phase is thought to involve the activation of Kupffer
cells (KCs), which release proinﬂammatory cytokines
and reactive oxygen species (ROS).5,6 The late phase
is characterized by increased expression of chemo-
kines and adhesion molecules and hepatic recruit-
ment of effector cells, which amplify the tissue dam-
age. The latter phenomenon is a feature common to
many other hepatic diseases. There is evidence sug-
gesting that hepatocyte injury occurs during the rela-
tively hypoxic early phase of IRI.7 ROS release is one
of the earliest and most important components of tis-
sue injury after the reperfusion of ischemic organs
and is a major contributor to hepatocyte death during
reperfusion.8 Moreover, diseases such as alcoholic
liver disease (ALD) are characterized by the chronic
accumulation of ROS. The source of hepatic ROS
remains controversial. Numerous studies have sug-
gested that hepatocyte damage is triggered by KC-
derived ROS,9,10 whereas others have shown that the
absence or elimination of KCs does not prevent tissue
damage in IRI.11 This suggests that other cells within
the liver, including hepatocytes, may be involved in
the pathophysiological production of ROS during IRI
and chronic hepatic inﬂammation.
Early work with rat hepatocytes suggested xanthine
oxidase as the main generator of ROS.12 However, the
xanthine oxidase inhibitors used in these studies are
now known to inhibit mitochondrial function, and mi-
tochondria are now accepted as the main source of
ROS within hepatocytes.13 Furthermore, the inhibition
of mitochondrial complexes I and III can ameliorate
ROS production in human hepatoma cell lines14 and
rat hepatocytes.15 Other enzymes, such as the ﬂavoen-
zyme nicotinamide adenine dinucleotide phosphate
(NADPH) oxidase, can also produce ROS in rat hepato-
cytes.16 The accumulation of excess intracellular ROS
induces cell death, and during hepatic IRI, hepatocytes
undergo both apoptosis and necrosis.17 Some studies
have supported apoptosis as the primary mode of
death,18 and others have supported necrosis.19 In real-
ity, it is uncertain whether the apoptosis and necrosis
observed in liver tissue are separate processes because
the terms primarily represent morphological descrip-
tions, and it has been suggested that apoptotic cells
not effectively cleared from inﬂammatory sites may
eventually assume a necrotic appearance (so-called
secondary necrosis). This led Jaeschke and Lemas-
ters20 to propose the term necroapoptosis, and it may
be that the 2 forms of cell death are in part related and
share some common intracellular pathways.
Despite these observations, little is known about the
relative contribution of endogenous hepatocyte ROS
production and its potential impact on hepatocyte cell
death after hypoxia and hypoxia/reoxygenation (H-R).
Much of our understanding of hepatic IRI comes from
studies of rodent hepatocytes and experimental models.
However, the response of human hepatocytes to hypoxia
and H-R is unknown. In addition, the research per-
formed with human hepatocytes has used cells isolated
from resected liver tissue from patients with neoplastic
disease.21 Whether cells from such normal sources can
be considered to truly reﬂect normal hepatocytes has
never to our knowledge been objectively studied.
The aim of our study was to characterize the
responses of human hepatocytes isolated from normal
liver tissue and diseased liver tissue to hypoxia and
H-R. Speciﬁcally, we delineated intracellular ROS
accumulation and cell death in primary human hepa-
tocytes isolated from normal liver tissue and diseased
liver tissue during hypoxia and H-R. Using an in vitro
model of warm hepatocyte IRI, we show for the ﬁrst
time highly variable responses of primary human he-
patocytes isolated from normal liver tissue, surgically
resected liver tissue, and diseased liver tissue to hy-
poxia and H-R. Although these ﬁndings have obvious
clinical implications within the transplant setting,
they are equally important for diseases in which local
cellular responses to hypoxia may shape the inﬂam-
matory and regenerative microenvironment. The appa-
rent variable responses of primary hepatocytes iso-
lated from normal tissue, resected normal tissue, and
diseased tissue are also important to workers study-
ing hepatocyte physiology and function ex vivo.
MATERIALS AND METHODS
Isolation of Human Hepatocytes
Liver tissue was obtained from fully consenting patients
undergoing transplantation for a variety of end-stage
liver diseases and from patients undergoing hepatic
resection for liver metastasis; normal donor tissue
exceeding surgical requirements was also used. Speciﬁ-
cally, normal donor tissue was obtained from the in situ
splitting of adult livers used for pediatric OLT. These
patients were 19 to 31 years old. The left lateral segment
was used for pediatric OLT, and this meant that tissue
could be procured from the right lobe. Human hepato-
cytes were isolated from explanted diseased livers from
patients with ALD, primary biliary cirrhosis, or primary
sclerosing cholangitis. Hepatocytes were also isolated
from tissue taken from patients who had undergone he-
patic resection for liver metastasis from colorectal carci-
noma. Liver tissue was obtained from surgical proce-
dures carried out at Queen Elizabeth Hospital
(Birmingham, United Kingdom). Ethical approval for the
study was granted by the local research ethics commit-
tee (reference number 06/Q702/61).
Importantly, all liver tissue, including explants, nor-
mal donor tissue, and normal resected tissue, was
obtained from patients with the same rigorous stand-
ard protocol. Brieﬂy, each liver specimen was in circuit
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and was supplied with blood under normoxic condi-
tions until the liver was explanted, split, or resected.
The only technical difference was that normal resected
tissue involved the removal of a speciﬁc portion of the
liver (usually right hemihepatectomy rather than the
whole organ). When liver tissue was obtained from
patients undergoing hepatic resection, all the patients
had received preoperative chemotherapy. After liver
explantation, splitting, or resection, all specimens were
placed on ice, immediately transported, and processed
within the laboratory. All hepatocyte isolation was car-
ried out within 6 hours of surgical explantation, split-
ting, or resection. Strict adherence to the procurement
and processing protocols ensured that any differences
observed between hepatocytes were results of disease
or altered physiology and were not explainable by dif-
ferences in the method of surgical tissue procurement
or subsequent processing.
Hepatocytes were isolated from fresh liver wedges
(60-156 g) with a 2-step collagenase protocol. Each
liver wedge was ﬁrst perfused with a nonrecirculating
wash buffer [10 mM 4-(2-hydroxyethyl)-1-piperazine
ethanesulfonic acid (pH 7.2), Sigma, Dorset, United
Kingdom] at 37C with a ﬂow rate of 75 mL/minute in
order to remove remaining blood within the liver. After
this, the wedge was perfused with a nonrecirculating
chelating solution [10 mM 4-(2-hydroxyethyl)-1-piper-
azine ethanesulfonic acid and 0.5 mM ethylene glycol
tetraacetic acid (pH 7.2), Sigma]. This was followed by
further perfusion with a nonrecirculating wash buffer
to remove any remaining ethylene glycol tetraacetic
acid. After this, the tissue was perfused with a recir-
culating enzymatic dissociation solution (Hank’s bal-
anced salt solution, Gibco, Paisley, United Kingdom)
with 5 mM calcium chloride (Sigma), 5 mM magne-
sium chloride (Sigma), 0.5% wt/vol collagenase
(Roche, Hertford, United Kingdom), 0.25% wt/vol pro-
tease (Sigma), 0.125% wt/vol hyaluronidase (Sigma),
and 0.05% wt/vol deoxyribonuclease (Sigma) at 37C
with a ﬂow rate of 75 mL/minute for 1 to 7 minutes.
After manual dissociation of the liver wedge, the sus-
pension was passed through a 250-lm nylon mesh
and then a 60-lm nylon mesh. The suspension was
then washed at 50g for 10 minutes at 4C in a supple-
mented medium (Dulbecco’s modiﬁed Eagle’s me-
dium, Gibco) with 10% vol/vol heat-inactivated fetal
calf serum (Gibco), 2 mM glutamine (Gibco), 20,000
U/L penicillin, and 20 mg/L streptomycin (Gibco). Im-
mediately after the washing, the cell viability was
determined by trypan blue dye exclusion. Hepatocytes
were plated in a supplemented medium and left for
2 hours. After this period, the medium was changed
to Williams’ E medium (Sigma) with 2 lg/mL hydro-
cortisone, 0.124 U/mL insulin, 2 mM glutamine,
20,000 U/L penicillin, and 20 mg/L streptomycin.
Cells were cultured for another 2 days before use.
Model of Warm H-R Injury
In experiments, hepatocytes were grown for 2 days at
37C with 5% CO2 in Williams’ E medium (Sigma) on
rat type 1 collagen-coated plates. Hepatocytes were
maintained in normoxia, placed into hypoxia for
24 hours, or placed into hypoxia for 24 hours and
then reoxygenated for 24 hours. Hypoxia was
achieved by the placement of cells in an airtight incu-
bator (RS Mini Galaxy A incubator, Wolf Laboratories,
United Kingdom) ﬂushed with 5% CO2 and 95% N2
until the oxygen content in the chamber reached
0.1%; this was veriﬁed with a dissolved-oxygen moni-
tor (DOH-247-KIT, Omega Engineering, United King-
dom). No previous studies had evaluated the response
of primary human hepatocytes to hypoxia and H-R.
Therefore, we modiﬁed a well-established model of
warm in vitro IRI.22,23 In preliminary experiments,
primary human hepatocytes were exposed to 5% or
1% oxygen for 2 or 24 hours, and no increase in ROS
accumulation or cell death was noted (data not
shown). Therefore, we used 0.1% oxygen in all subse-
quent experiments for 24 hours. Additionally, Wil-
liams’ E medium was preincubated in the hypoxic
chamber in a sterile container (which allowed gas
equilibration) for 8 hours before experiments were
carried out; this resulted in a ﬁnal oxygen concentra-
tion of <0.1% as measured with the dissolved-oxygen
meter. When it was appropriate, after 24 hours of hy-
poxia, the medium was aspirated and replaced with a
fresh, warmed, oxygenated medium, and the cells
were returned to normoxic conditions. This was
deﬁned as the beginning of reoxygenation. In experi-
ments involving ROS inhibitors/antioxidants, all
reagents were made fresh as stock solutions and were
added with the correct dilutional factor to the relevant
experimental wells. Speciﬁcally, 100 mM N-acetylcys-
teine (NAC; Sigma) was dissolved in molecular-grade
water, 1 mM rotenone (Rot; Sigma) was dissolved in
chloroform, and 1 mM diphenyliodonium (DPI; Sigma)
was dissolved in dimethyl sulfoxide; they were diluted
appropriately to produce working concentrations of
20 mM, 2 lM, and 10 lM, respectively. In experiments
using inhibitors/antioxidants, solvent-alone controls
were used to ensure no vehicle effects. In addition, in
experiments using inhibitors/antioxidants, agents
were added at the time of placement of the cells into
hypoxia or reoxygenation.
Flow Cytometry
ROS production, apoptosis, and necrosis were deter-
mined with a 3-color reporter assay system. ROS accu-
mulation was determined with the ﬂuorescent probe
20,70-dichloroﬂuorescin diacetate.24 This probe is cell-
permeable and, once inside a cell, is cleaved by intracel-
lular esterases into 20,70-dichloroﬂuorescin (DCF; Merck,
Nottingham, United Kingdom), which is then rendered
cell-impermeable. DCF is then able to react with intra-
cellular ROS (speciﬁcally hydrogen peroxide) and pro-
duce a ﬂuorescent signal detectable on the ﬂuorescein
isothiocyanate (FITC) channel. The signal is directly pro-
portional to the level of intracellular ROS present.
Apoptosis was determined via the labeling of cells
with annexin V (Molecular Probes, Paisley, United
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Kingdom), which detects exposed phosphatidylserine
on the cell membrane. 7-Aminoactinomycin D (7-AAD;
Molecular Probes) is a vital dye that binds to DNA,
enters cells only once the cell membrane is disrupted,
and is indicative of cellular necrosis. To ensure the
consistency of the ﬂow cytometry data, each human
hepatocyte preparation was labeled with DCF alone,
annexin V alone, and 7-AAD alone to ensure that the
cells were labeled and that the ﬂow cytometry data
could be compensated for the crossover of ﬂuorophore
emission spectra. The same ﬂow cytometry protocol
was used for all experiments of the study; this meant
that voltages for all markers were constant for all
human hepatocyte preparations, so the internal con-
sistency of the experiments was ensured.
After appropriate treatment of the cells, the medium
was aspirated and replaced with Hank’s balanced salt
solution (Gibco) without calcium or magnesium. DCF
(30 lM) was added, and the cells were incubated for
20 minutes in the dark at 37C. Next, the cells were
trypsinized and washed extensively in a ﬂuorescence-
activated cell sorting buffer [phosphate-buffered sa-
line (pH 7.2) with 10% vol/vol heat-inactivated fetal
calf serum, Gibco]. Cells were then labeled with
annexin V and 7-AAD for 15 minutes while they were
on ice, and samples were immediately subjected to
ﬂow cytometry. At least 20,000 events were recorded
within the gated region of the ﬂow cytometer for each
human hepatocyte cell preparation under each experi-
mental condition. Only the cells within the gated
region were used to calculate the mean ﬂuorescence
intensity (MFI).
Statistical Analysis
Data analysis was carried out with SPSS software
(version 13.0). All values are presented as means and
standard errors unless otherwise noted. Statistical
analysis was carried out with the Student t test.
RESULTS
Variable ROS Responses to Hypoxia and H-R of
Human Hepatocytes Isolated From Patients
With Different Liver Diseases
Figure 1 and Table 1 show ROS production and accu-
mulation in primary human hepatocytes isolated from
normal liver tissue, normal resected liver tissue, and
diseased liver tissue. Hepatocytes isolated from nor-
mal livers, ALD liver tissue, and normal resected liver
tissue showed similar and consistent responses to hy-
poxia and H-R. Interestingly, normal human hepato-
cytes had little basal intracellular ROS. However, after
Figure 1. Hypoxia and H-R mediate ROS accumulation in human hepatocytes. Representative flow cytometry plots are shown to
illustrate the effects of hypoxia and H-R on ROS accumulation in human hepatocytes isolated from normal liver tissue, diseased
liver tissue, and normal resected liver tissue. Vertical ellipses mark the areas of interest within the plots. The area to the left of
each ellipse represents cell debris. The reason that the cell debris is included within the plots is that human hepatocytes vary
considerably in size; therefore, to include all viable human hepatocytes in the analysis, a large gate was required on the flow
cytometer, and this by necessity included the cell debris. The gate is shown on the corresponding representative FS-SS plots
located to the left of each flow cytometry plot. The FS-SS plots are from the H-R samples of each preparation, but similar plots
were obtained during normoxia and hypoxia (data not shown). Although in the flow cytometry plot of the normal resected liver
tissue there are 2 peaks to the left of the ROS peak, these both represent debris; this has been confirmed by 7-AAD staining and
their size on the FS-SS plots. The data are representative of 4 normal hepatocyte preparations, 4 biliary disease preparations, 3
ALD preparations, and 9 resected normal liver preparations.
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exposure to hypoxia and H-R, normal human hepato-
cytes had signiﬁcantly increased intracellular ROS
accumulation. Hepatocytes isolated from ALD liver
tissue and normal resected liver tissue showed similar
responses with respect to ROS accumulation during
hypoxia and H-R but had greater basal intracellular
ROS contents; this possibly reﬂected their continual
exposure to an inﬂammatory microenvironment.25 He-
patocytes isolated from the tissue of patients with the
biliary diseases, primary biliary cirrhosis and primary
sclerosing cholangitis, had very low basal levels of
ROS production similar to those detected in hepato-
cytes from normal livers, but they showed a 22-fold
increase in ROS production during hypoxia and a
reduction in ROS accumulation during H-R. This may
be a reﬂection of increased engagement of hepatocyte
cytosolic antioxidant defenses, which is possibly a
result of cholestasis, a common feature of these
diseases.
ROS Activation Mediated Hepatocyte Apoptosis
and Necrosis
We next assessed the effects of hypoxia and H-R on
human hepatocyte cell death. Previous in vitro studies
have shown that human hepatoma cell lines26 and
murine27 and rodent hepatocytes28 undergo cell death
during hypoxia and H-R. We have found that human
hepatocytes isolated from normal liver tissue and dis-
eased liver tissue experience increased apoptosis and
necrosis during hypoxia and H-R (Fig. 2A,B). The level
of human hepatocyte apoptosis and necrosis during
hypoxia and H-R mirrored the level of intracellular
ROS production within the particular type of hepato-
cyte. The decrease in ROS production observed in he-
patocytes isolated from the tissue of patients with bili-
ary diseases was accompanied by a concomitant
decrease in apoptosis and necrosis; this conﬁrmed
the association of ROS with apoptotic and necrotic
cell death. The highest levels of ROS were seen in he-
patocytes isolated from normal resected liver tissue.
Despite the increase in intracellular ROS in normal
hepatocytes isolated from resected liver tissue, the
level of apoptosis or necrosis did not increase; this
suggested an important difference in the metabolic ac-
tivity or protective mechanisms of these cells. More-
over, hepatocytes from normal resected tissue did
have higher basal levels of both apoptosis and
necrosis.
Effect of ROS Inhibitors on ROS Accumulation
Antioxidants and inhibitors of ROS generation have
been shown to abrogate human hepatoma cell line
death during hypoxia.26 Figure 3 shows the effects of
antioxidants, mitochondrial chain inhibitors, and
NADPH oxidase inhibitors on primary human hepato-
cyte ROS production during H-R. Similar results were
observed during normoxia and hypoxia (data not
shown). NAC acts as a glutathione precursor; it enters
cells and interacts with and detoxiﬁes free radicals by
nonenzymatic reactions. It is deacetylated to form cys-
teine, which supports the biosynthesis of glutathione,
one of the most important components of the intracel-
lular antioxidant system.29 NAC almost completely
inhibited ROS production in all hepatocytes during
H-R. Rot, a mitochondrial complex I inhibitor, was
also able to inhibit ROS production in hepatocytes
isolated from all sources, and this conﬁrmed mito-
chondria as a major source of endogenous ROS in
human hepatocytes. The inhibition of ROS by Rot was
substantial but not as great as that observed with
NAC. The production of ROS in the presence of mito-
chondrial inhibition implies the involvement of other
mechanisms in human hepatocytes. Accordingly, we
found that the ﬂavoenzyme NADPH oxidase was also
involved in ROS production within the hepatocyte.
The speciﬁc NADPH oxidase inhibitor DPI signiﬁcantly
decreased ROS production in all human hepatocytes.
Thus, although the overall effect was not as great as
that of Rot, NADPH oxidase is also an important
source of ROS in human hepatocytes. In all cases, ve-
hicle controls caused no inhibition of intracellular he-
patocyte ROS levels (data not shown).
Effects of ROS Inhibitors on Human Hepatocyte
Apoptosis and Necrosis
Because NAC, Rot, and DPI all inhibited ROS, we
assessed whether this decrease in ROS affected
TABLE 1. ROS Accumulation in Human Hepatocytes During Hypoxia and H-R
Normal Biliary Cirrhosis ALD Resected
Normoxia 30.3 (13.3-53.5) 11.9 (6.2-21.1) 226.5 (217.1-247.1) 352.8 (256.4-450.5)
Hypoxia 121.9 (39.6-166.2)* 255.2 (139.9-444.0)* 259.5 (229.2-281.2) 377.1 (284.3-547.2)
H-R 271.1 (217.7-370.0)*,† 102.6 (35.2-151.0)* 294.7 (278.2-311.1) 506.1 (332.2-874.0)
NOTE: The mean ROS accumulation for human hepatocytes isolated from normal liver tissue, diseased liver tissue, and
normal resected liver tissue is shown for each of the 3 experimental conditions. Data are expressed as MFIs. Numbers in
parentheses are the ranges of MFI readings for each experimental condition. The MFI values have been derived from the
cells within the ellipses shown in Fig. 1. The data are representative of 4 normal hepatocyte preparations, 4 biliary disease
preparations, 3 ALD preparations, and 9 normal resected liver preparations.
*P < 0.05 versus normoxia.
†P < 0.05 versus hypoxia.
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Figure 2. Hypoxia and H-R induce human hepatocyte apoptosis and necrosis. (A) Representative flow cytometry plots are shown
to illustrate the effects of hypoxia and H-R on the apoptosis and necrosis of human hepatocytes isolated from normal liver tissue,
diseased liver tissue, and normal resected liver tissue. The areas of interest within the plots are marked by vertical ellipses. Just as
in the ROS plots shown in Fig. 1, the area to the left of each vertical ellipse represents cell debris. The data are representative of 4
normal hepatocyte preparations, 4 biliary disease preparations, 3 ALD preparations, and 9 normal resected liver preparations. (B)
The bar charts show pooled data illustrating the level of apoptosis and necrosis in human hepatocytes isolated from normal tissue,
diseased tissue, and normal resected tissue during hypoxia and H-R. The data are shown as fold over the basal level. The levels of
apoptosis and necrosis occurring during normoxia have been taken as the basal levels. The data are expressed as means and
standard errors. The data are representative of 4 normal hepatocyte preparations, 4 biliary disease preparations, 3 ALD
preparations, and 9 normal resected liver preparations. *P < 0.05; **P < 0.05.
1308 BHOGAL ET AL. LIVER TRANSPLANTATION, November 2010
human hepatocyte apoptosis and necrosis. Data for
H-R are shown in Fig. 4; similar results were observed
during normoxia and hypoxia (data not shown). The
reduction in endogenous ROS levels in human hepa-
tocytes treated with the various inhibitors led to sig-
niﬁcantly decreased hepatocyte apoptosis (Fig. 4A)
and necrosis (Fig. 4B). In line with the more potent
effect of NAC on ROS inhibition, the effects of NAC
were the greatest. Rot and DPI also decreased apopto-
sis and necrosis during H-R. Moreover, ROS inhibition
abrogated apoptosis in human hepatocytes isolated
from tissue taken from patients with different types of
hepatic diseases but only partially inhibited hepato-
cyte necrosis. These data provide clear evidence that
endogenous ROS production by mitochondria and
NADPH oxidase drives human hepatocyte apoptosis
and necrosis during H-R.
DISCUSSION
Although hypoxia is a feature of hepatic IRI associated
with hepatic surgery, it may also occur during chronic
liver inﬂammation or infection. Therefore, by deﬁning
the effects of hypoxia on liver physiology, we can
obtain important information regarding the develop-
ment of future therapeutics.
Hepatocytes have conventionally been considered
relatively insensitive to IRI because of their extensive
antioxidant defense mechanisms and their existence
within the comparatively hypoxic hepatic environ-
ment.30 However, numerous in vitro and in vivo stud-
ies have reported deleterious effects of IRI on hepato-
cytes, although the effects of hypoxia and H-R on
human hepatocytes are unknown. Our data reveal
that hepatocytes are susceptible to apoptosis and
necrosis induced in response to hypoxia and H-R, and
we report for the ﬁrst time that human hepatocytes
isolated from patients with different hepatic diseases
show variable responses to hypoxia and H-R.
Hypoxia is known to cause dysfunction of the mito-
chondrial electron transport chain and thus lead to
an increase in ROS; this is accentuated by reoxygena-
tion and can result in cell death.31 Hepatocytes iso-
lated from normal donor livers, ALD livers, and unin-
volved livers from hepatic resections exhibit this
classic response to hypoxia and H-R. Interestingly,
hepatocytes isolated from ALD livers and resected
liver tissue have high basal levels of ROS production,
and these are then augmented by hypoxia and H-R;
however, normal hepatocytes and hepatocytes isolated
from the livers of patients with biliary cirrhosis show
very little basal ROS production. These differences are
likely due to the particular inﬂammatory microenvir-
onment and milieu to which each hepatocyte popula-
tion has been exposed. For example, many mediators
found in ALD patients are known to increase ROS,25
and hepatocytes isolated from hepatic resections will
have been exposed to chemotherapy, a treatment
known to increase intracellular ROS.32 Hepatocytes
isolated from patients with biliary cirrhosis had lower
levels of ROS during H-R, and this possibly reﬂected
the up-regulation of the antioxidant defenses in these
particular cells. The differential responses of hepato-
cytes isolated from patients with different hepatic dis-
eases are unlikely to be attributable to the method of
isolation because the liver tissues were procured and
processed according to an identical and stringent pro-
tocol. The precise cellular mechanisms underlying he-
patocyte responses to hypoxia and H-R remain the
subject of ongoing research within our laboratory.
It has been suggested previously that hepatocytes
are bystanders in IRI and are targeted by the inﬂam-
matory process.2 We now propose that they have the
capacity to actively participate in it primarily through
the production of ROS. The functional relevance of
ROS is emphasized by our ﬁnding that increased lev-
els of endogenous ROS are clearly linked to hepato-
cyte apoptosis and necrosis. This has particular rele-
vance for liver diseases in which hepatocytes are
exposed to relative hypoxia and may be responsible
for perpetuating injury. We have demonstrated that
ROS can directly activate apoptosis and necrosis and
thereby support the suggestion of Jaeschke and
Lemasters20 that common pathways may at least in
part regulate both processes. Moreover, ROS derived
from mitochondria and cytosolic NADPH oxidase are
crucial for regulating both apoptosis and necrosis,
and their inhibition signiﬁcantly improves human he-
patocyte viability during hypoxia and H-R. The ﬁnal
mode of cell death is likely to be dictated by the intra-
cellular adenosine triphosphate content.33 Interest-
ingly, ROS inhibition had a greater effect on reducing
human hepatocyte apoptosis and only partially inhib-
ited hepatocyte necrosis. Although ROS does contrib-
ute to human hepatocyte necrosis, it is likely that a
Figure 3. Antioxidants, mitochondrial chain inhibitors, and
NADPH oxidase inhibitors reduce human hepatocyte ROS
production during H-R. Human hepatocytes isolated from
normal livers, diseased livers, and normal resected livers were
treated with 20 mM NAC, 2 lM Rot, or 10 lM DPI during H-R.
ROS accumulation was determined by flow cytometry as
described in the Materials and Methods section. ROS production
data are shown as MFIs and are based on the MFI readings
taken from cells within the ellipse region shown in Fig. 1. The
data are expressed as means and standard errors. The data are
representative of 3 normal hepatocyte preparations, 3 biliary
disease preparations, 3 ALD preparations, and 5 normal
resected liver preparations. *P < 0.01; **P < 0.01.
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number of factors, including calcium overload, cal-
pain activation, and lysosome rupture, force the cell
to undergo necrosis.34 In contrast, Wang et al.35 dem-
onstrated that ROS derived from mitochondria
directly activated apoptosis in Chang human hepato-
cytes. Accordingly, the inhibition of ROS and, in par-
ticular, mitochondrial ROS had a greater effect on
reducing hepatocyte apoptosis. As previously noted,
hepatocytes undergoing necrosis will release intracel-
lular ROS into the liver parenchyma and induce both
hepatocyte and endothelial cell activation.36 There-
fore, our observations have implications not only for
hepatic IRI but also for liver diseases in which chronic
hypoxia leads to continued ROS production and
ongoing liver damage. In separate experiments, we
exposed human hepatic sinusoidal endothelial cells
(HSECs) to the same in vitro model of warm IRI.
HSECs did not increase intracellular ROS during hy-
poxia and H-R and did not undergo any signiﬁcant
level of cell death during hypoxia and H-R (R.H.B.,
unpublished data, 2010). These observations show
that liver epithelial and endothelial cells have different
responses to hypoxia and H-R, and these differences
are likely to shape the hepatic inﬂammatory microen-
vironment. On the basis of our data, we speculate
that in warm IRI, hepatocyte ROS (not HSEC-derived
ROS) may be important regulators of hepatic injury.
The precise role of HSECs during warm IRI is beyond
the scope of this particular study.
In rat livers, treatment with antioxidants can pre-
vent IRI.37 In limited human studies, ischemia has
induced the expression of ROS scavengers within the
liver.38 Despite the presence of induced antioxidant
mechanisms, human hepatocytes isolated from nor-
mal livers, the livers of patients with ALD, and the
livers of patients with biliary cirrhosis do not appear
to be protected against cell death during hypoxia
and H-R. Hepatocytes isolated from normal resected
liver tissue were, however, surprisingly resistant to
ROS-mediated apoptosis and necrosis. This ﬁnding
has important implications for research involving
human hepatocytes and suggests that studies should
be interpreted in the context of the hepatocyte
source; hepatocytes isolated from resected hepatic
tissues of patients with liver tumors are likely to
respond differently to physiological stress. As men-
tioned earlier, the reason for this difference remains
unknown. Furthermore, which hepatocyte response
reﬂects the true physiological response remains to be
determined. In separate experiments, NAC, Rot, and
DPI were used to treat HepG2, Huh7, and PLC/PRF/
5 human hepatoma cell lines during hypoxia and H-R.
These inhibitors induced overwhelming cell death in
these particular cell lines, and this indicated vastly dif-
ferent responses to hypoxia and H-R in comparison
with primary hepatocytes (data not shown). Therefore,
although previous studies have shown cytoprotective
effects of antioxidants and ROS inhibitors, we report
here for the ﬁrst time that the inhibition of mitochon-
drial and NADPH oxidase–derived ROS reduces pri-
mary human hepatocyte apoptosis and necrosis.
A single strategy aimed at the amelioration of the
harmful effects produced by IRI has not yet been
adopted into general clinical practice. Experimental
interventions to reduce ROS have shown potential for
minimizing liver injury in various models. ROS scav-
engers,39 thioredoxin mimetics,40 and the delivery of
antioxidant genes41 have been shown to partially sup-
press the effects of IRI. However, the clinical applica-
tion of such compounds has been limited for toxico-
logical and technical reasons. NAC, however, has
clinical potential because it is known to be well toler-
ated at doses that should be clinically effective.
Indeed, NAC is used clinically in several settings; for
example, it is used as a hepatoprotective agent for
acute liver failure and acetaminophen toxicity. Fur-
thermore, although NAC administration has been
shown to improve hepatic microcirculation and bile
ﬂow after hepatic IRI,7 we now show that NAC can
also reduce all ROS production in human hepatocytes
with a concomitant decrease in apoptosis and necro-
sis during normoxia, hypoxia, and H-R. Recent stud-
ies have suggested that pleiotropic compounds are
required to treat IRI because of the diverse nature of
the problem.42 We suggest that exogenous NAC could
be a straightforward, practical, and beneﬁcial strategy
for ameliorating human hepatocyte cell death during
IRI. Indeed, a recent randomized study showed that
the systemic infusion of NAC before liver procurement
reduced graft dysfunction and early graft loss after
liver transplantation.43
Although some authors have challenged the patho-
physiological relevance of intracellular oxidant stress
during reperfusion,44 we have clearly shown that he-
patocyte ROS generated by mitochondria and NADPH
oxidase can lead directly to signiﬁcant hepatocyte cell
death; we suggest that although other sources of
ROS, such as neutrophils and KCs, are capable of
contributing to tissue ROS accumulation in IRI, they
may not be the only pathways leading to ROS-
Figure 4. (A) ROS accumulation in human hepatocytes during
H-R mediates apoptosis. Human hepatocytes isolated from
normal tissue, diseased tissue, and normal resected tissue were
treated with 20 mM NAC, 2 lM Rot, or 10 lM DPI during H-R,
and the percentages of cells that were stained with both the ROS
probe DCF and the apoptotic marker annexin V were assessed
by flow cytometry. The cross-plots show ROS on the x axis and
apoptosis on the y axis. The percentages of human hepatocytes
that were stained with both DCF and annexin V are shown in
parentheses. The data are representative of 3 normal hepatocyte
preparations, 3 biliary disease preparations, 3 ALD
preparations, and 5 normal resected liver preparations. *P <
0.001. (B) ROS accumulation in human hepatocytes during H-R
mediates necrosis. Human hepatocytes isolated from normal
tissue, diseased tissue, and normal resected tissue were treated
with 20 mM NAC, 2 lM Rot, or 10 lM DPI during H-R, and the
percentages of cells that were stained with both the ROS probe
DCF and the necrotic marker 7-AAD were assessed by flow
cytometry. The cross-plots show ROS on the x axis and necrosis
on the y axis. The percentages of human hepatocytes that were
stained with both DCF and 7-AAD are shown in parentheses.
The data are representative of 3 normal hepatocyte preparations,
3 biliary disease preparations, 3 ALD preparations, and 5
normal resected liver preparations. *P < 0.01.
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mediated hepatocyte damage. An important caveat to
our data is that oxidative stress in human hepato-
cytes after hypoxia and H-R may differ between hypoxia
at 4C and hypoxia at 37C.45 Therefore, although these
data can be applied to the transplant setting, they are
not wholly reﬂective of the in vivo situation.
In summary, our data show that human hepatocyte
responses to hypoxia and H-R are determined by their
particular microenvironment. Both apoptosis and ne-
crosis are regulated by endogenous human hepato-
cyte ROS, and inhibitors of ROS generation signiﬁ-
cantly improve hepatocyte viability by reducing ROS
generation. The use of NAC offers an opportunity to
modulate hepatic IRI and improve patient outcomes
after OLT, possibly through its addition to preserva-
tion ﬂuids. In addition, our studies demonstrate for
the ﬁrst time that hepatocytes taken from normal tis-
sue, normal resected tissue, and diseased tissue may
vary considerably in their functional and metabolic
responses to hypoxic stress.
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